The Blood Screening Market covers the diagnostic technologies, instruments, reagents, and services used to test donated blood before it is released for transfusion. Screening plays an essential role in identifying infectious diseases, blood-group incompatibilities, and other potential risks that could affect recipients. Common technologies include nucleic acid amplification testing (NAT), enzyme-linked immunosorbent assays (ELISA), rapid testing, and next-generation sequencing.
The importance of blood screening continues to increase as blood collection volumes rise and healthcare systems place greater emphasis on transfusion safety. According to the latest Market Research Future analysis, the global Blood Screening Market was valued at USD 3.46 billion in 2025 and is projected to increase from USD 3.77 billion in 2026 to USD 8.19 billion by 2035, representing a CAGR of 9.0% during 2026–2035. North America currently leads the market, while Asia-Pacific is expected to experience the fastest expansion during the forecast period.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/6899
Market Drivers
Increasing Blood Donation Volumes:
The growing need for blood and blood components is creating a larger testing workload for blood banks and transfusion centers. Every donated unit must undergo appropriate screening before it can safely enter the blood supply. As donation volumes increase, demand for screening reagents, kits, instruments, and laboratory services also rises.
Stronger Focus on Transfusion Safety:
Healthcare organizations and regulatory authorities continue to strengthen standards surrounding blood collection and testing. Screening programs are increasingly designed to identify infectious agents during earlier stages of infection, helping reduce the possibility of transfusion-transmitted diseases.
Growing Adoption of Molecular Screening:
Nucleic acid amplification testing has become an important component of modern blood screening because it can identify pathogen genetic material before antibodies or other conventional markers become detectable. NAT accounted for approximately 45% of market revenue in 2025, making it the leading technology segment.
Increasing Automation in Blood Banks:
Large blood centers are increasingly replacing manual and semi-automated workflows with integrated systems capable of sample handling, testing, result interpretation, and reporting. Automation can improve throughput, reduce repetitive laboratory work, and provide more consistent testing processes.
Expansion of Infectious Disease Screening:
Infectious disease testing represents the largest screening-target category, accounting for approximately 53% of market share in 2025. Screening for HIV, hepatitis B, hepatitis C, and other transfusion-relevant pathogens remains a central requirement for maintaining a safe blood supply.
Development of Advanced Pathogen Detection:
The emergence of new infectious diseases and pathogen variants is encouraging blood centers to consider broader testing panels. Advanced molecular platforms and sequencing technologies can potentially help identify pathogens that are difficult to detect using conventional assays.
Market Challenges
High Cost of Advanced Screening Equipment:
Fully automated molecular screening systems require significant capital investment. This can create difficulties for smaller blood banks and healthcare facilities, particularly in countries where funding for transfusion infrastructure is limited.
Need for Skilled Laboratory Personnel:
Although automation is increasing, qualified professionals are still needed to manage screening workflows, quality control, equipment maintenance, validation, and interpretation of complex or inconclusive results.
Regulatory Complexity:
Blood screening is highly regulated because testing errors can have serious consequences for transfusion recipients. Manufacturers and healthcare organizations must meet stringent requirements for analytical performance, quality assurance, validation, and reporting.
Supply Chain Dependence:
Blood screening laboratories depend on reliable supplies of reagents, consumables, calibrators, and replacement components. Disruptions in international supply chains can affect testing capacity and increase operational costs.
Unequal Access to Advanced Testing:
High-income countries generally have access to sophisticated molecular screening platforms, whereas some low- and middle-income regions continue to rely heavily on conventional or rapid testing. Differences in infrastructure, funding, and laboratory capacity can limit market expansion in underserved areas.
Browse In-depth Market Research Report on Blood Screening Market:
https://www.marketresearchfuture.com/reports/blood-screening-market-6899
Market Segmentation
By Product:
Reagents and Kits: Reagents and kits represented approximately 51% of the market in 2025. Their recurring use for every screened donation makes them a major source of revenue for manufacturers.
Instruments: Screening instruments include molecular analyzers, immunoassay systems, blood-typing equipment, and automated laboratory platforms. The instruments segment is expected to grow at approximately 10.6% CAGR through 2035 as blood centers modernize their equipment.
Software and Services: Software platforms and laboratory services support test management, data processing, reporting, connectivity, and integration with blood-bank information systems.
By Technology:
Nucleic Acid Amplification Testing: NAT is widely used to identify pathogen genetic material and reduce the diagnostic window period for important transfusion-transmitted infections.
Enzyme-Linked Immunosorbent Assay: ELISA remains an established screening method because of its scalability, relatively low cost, and broad application across infectious disease testing.
Rapid Tests: Rapid testing can be useful in settings where centralized laboratory infrastructure is limited. These systems provide faster results but may have different sensitivity characteristics compared with advanced molecular platforms.
Next-Generation Sequencing: NGS is an emerging technology within blood screening. It is expected to grow at approximately 11.9% CAGR through 2035 because of its potential for detecting emerging and variant pathogens.
By Screening Target:
Infectious Disease Screening: This is the largest segment and includes screening for HIV, hepatitis B, hepatitis C, syphilis, and other pathogens that may pose transfusion risks.
Blood Group Typing: Blood-group testing is essential for determining compatibility between donated blood and recipients. It includes ABO, Rh, and other clinically important blood-group systems.
Other Screening Targets: This category includes specialized testing for conditions and pathogens that may become relevant because of regional epidemiology, emerging diseases, or changes in blood-safety requirements.
By End User:
Blood Banks: Blood banks represented approximately 63% of end-user demand in 2025. These facilities process large numbers of donations and require reliable, high-throughput screening technologies.
Hospitals: Hospitals use screening systems through in-house transfusion services and blood banks, particularly for urgent and routine transfusion requirements.
Clinical Laboratories: Clinical laboratories provide specialized and confirmatory testing and are expected to experience approximately 11.0% CAGR through 2035.
Regional Insights
North America:
North America held approximately 38% of the global Blood Screening Market in 2025. Strong regulatory standards, advanced blood-bank infrastructure, widespread adoption of automated testing, and established voluntary blood donation systems support the region’s leading position.
Europe:
Europe represents another major market, accounting for approximately 27% of global revenue. The region’s established transfusion networks, stringent blood-safety standards, and continued investment in pathogen detection technologies support market development.
Asia-Pacific:
Asia-Pacific is projected to be the fastest-growing region, with a CAGR of approximately 10.7% through 2035. Increasing healthcare expenditure, improvements in blood-bank infrastructure, rising voluntary donation rates, and government-led transfusion-safety programs in countries such as China and India are creating strong opportunities.
South America:
South American countries are gradually strengthening their blood-screening infrastructure. Greater emphasis on voluntary donation, infectious disease surveillance, and standardized testing is expected to increase demand for modern screening technologies.
Middle East & Africa:
The Middle East and Africa represent significant long-term opportunities because many healthcare systems are investing in blood-bank modernization. Expanding laboratory infrastructure and international efforts to improve transfusion safety are expected to encourage adoption of advanced screening systems.
Key Players
Grifols S.A.
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Bio-Rad Laboratories
Ortho Clinical Diagnostics
Immucor
Hologic, Inc.
Quotient Limited
Beckman Coulter
Siemens Healthineers
These companies compete through improvements in molecular testing, immunoassay platforms, blood-group testing, automation, laboratory connectivity, and integrated transfusion-management solutions.
Future Outlook
The Blood Screening Market is expected to maintain strong momentum as blood centers modernize testing infrastructure and regulators continue to emphasize transfusion safety. Market Research Future projects the market to reach USD 8.19 billion by 2035 from USD 3.46 billion in 2025, representing a CAGR of 9.0% during 2026–2035.
Automation will remain an important part of the industry’s future. Large blood centers are increasingly looking for platforms that can handle higher sample volumes while reducing manual intervention and connecting screening results with digital blood-bank systems.
Molecular diagnostics are also expected to remain a major area of innovation. Multiplex NAT platforms can screen for several pathogens within a single workflow, while next-generation sequencing could eventually provide broader surveillance capabilities for emerging or previously unidentified pathogens.
Point-of-care molecular testing may create additional opportunities in regions where donations must travel long distances to centralized laboratories. Compact and easier-to-use systems could help extend advanced screening capabilities to rural collection centers and underserved communities.
Artificial intelligence may also contribute to improved laboratory workflows by supporting result interpretation, inventory planning, anomaly detection, and transfusion-service management. At the same time, manufacturers are likely to focus on reducing reagent consumption, laboratory waste, and energy requirements as sustainability becomes more important in healthcare procurement.
Overall, rising blood donation volumes, stricter transfusion-safety requirements, automation, molecular diagnostics, and expanding healthcare infrastructure are expected to support the long-term Growth of the Blood Screening Market.
Related Report:
Explore additional reports to understand evolving market landscapes:
Chronic Kidney Disease Market Size
Chronic Kidney Disease Market Share
Clinical Trial Management System Market Trends
Clinical Trial Management System Market Growth
Clinical Trial Management System Market Demand
About Market Research Future:
Market Research Future (MRFR) is a global market research company providing market intelligence and consulting services across healthcare, medical devices, pharmaceuticals, life sciences, technology, and other industries. Its research covers market size, segmentation, regional performance, competitive developments, emerging technologies, and future opportunities.
Follow Us:
LinkedIn | Twitter
Contact:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
